Blood targets of adjuvant drugs against covid19

5Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiser-otoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle.

Cite

CITATION STYLE

APA

Di Micco, P., Di Micco, G., Russo, V., Poggiano, M. R., Salzano, C., Bosevski, M., … Fontanella, A. (2020). Blood targets of adjuvant drugs against covid19. Journal of Blood Medicine, 11, 237–241. https://doi.org/10.2147/JBM.S256121

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free